Related Experiment Video

Updated: Apr 14, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.2K

Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite

Daisuke Yabe1, Hitoshi Kuwata, Ryota Usui

  • 1Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital , Osaka , Japan.

Current Medical Research and Opinion
|April 29, 2015
PubMed

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively manage type 2 diabetes by improving glycemic control and body weight with minimal hypoglycemia. Further long-term trials are needed to confirm benefits and cost-effectiveness.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes management requires comprehensive assessment of composite endpoints, including HbA1c, body weight, and metabolic parameters.
  • Optimal glycemic control, alongside management of body weight, blood pressure, and lipids, is crucial for preventing micro- and macro-vascular complications.

Purpose of the Study:

  • To evaluate the established role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes management.
  • To highlight the multifaceted benefits of GLP-1RAs beyond glucose lowering.

Main Methods:

  • Review of available data on GLP-1RAs in type 2 diabetes.
  • Analysis of therapeutic targets for complication prevention.

Main Results:

  • GLP-1RAs demonstrate significant glucose-lowering effects with a low risk of hypoglycemia.
  • These agents also positively impact body weight, blood pressure, and lipid levels.
  • Current data suggest predominantly beneficial effects of GLP-1RAs.

Conclusions:

  • GLP-1RAs are a key component of type 2 diabetes treatment, offering broad metabolic benefits.
  • Long-term data on composite endpoints, quality of life, and cost-effectiveness require further investigation through prospective trials.
  • Healthcare professionals must remain vigilant for rare adverse events associated with GLP-1RA use.
Keywords:
GLP-1 receptor agonistscomposite end-pointscost effectivenesshealth-related quality of lifetype 2 diabetes

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.8K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.9K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
987
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
988
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K